Psychiatry: An SOS Call

Social policies shaped the practice of psychiatry in the past. As the discipline becomes ever more scientific, the effects of social policy on patient well-being must not be ignored.

Written byRobert E. Becker
| 4 min read

Register for free to listen to this article
Listen with Speechify
0:00
4:00
Share

© ROY SCOTT/IKON IMAGES/CORBISDuring the early 20th century American psychiatry fell under the influence of psychoanalysis. At mid-century, psychiatry broke with psychoanalysis to align more closely with scientific medicine. As psychiatry turned toward the biological sciences, state hospitals discharged thousands of severely mentally ill patients with prescriptions in hand, and federally funded mental-health initiatives, ill-prepared to cope with the deluge, sprang up in communities across the nation. This led to a split in the practice of psychiatry. For psychiatrists concerned with the brain as an entry point into a new scientific era, neurochemistry and neuropharmacology filled the void left by psychoanalysis. For psychiatrists working in the emerging community-health programs, a wide range of additional activities and their supporting sciences—sociology, psychology, and economics, as well as vocational, transcultural, and other studies—became relevant to providing improved patient care. During the ensuing years, the brain sciences flourished, while services in communities, affected by social policies, withered. Today, psychiatrists debate whether psychiatry should become an applied neuroscience focused on brain functions or a research enterprise driven by the clinical needs of patients and communities.

Clinician psychiatrists find current academic priorities and the policies that shape them unbalanced regarding which sciences and practices best serve psychiatric patients. By abruptly terminating federal funding of community services, the Reagan Administration precipitated a continuing decline in vital corollary adjuncts to psychiatric treatment. The use of drugs to manage mental disorders and the managed-care practices of insurance companies encouraged psychiatrists to abandon working in community health clinics in favor of practicing in offices. Federal policies that leave clinical drug development to industry, and the dependence on pharmaceutical companies for funding, constrained academic research. Academics and universities began to profit by selling their discoveries to such companies. Each of these developments has favored the tilt toward neuroscience and undermined psychiatry’s integration of other disciplines.

Psychiatry’s ...

Interested in reading more?

Become a Member of

The Scientist Logo
Receive full access to digital editions of The Scientist, as well as TS Digest, feature stories, more than 35 years of archives, and much more!
Already a member? Login Here
February 2026

A Stubborn Gene, a Failed Experiment, and a New Path

When experiments refuse to cooperate, you try again and again. For Rafael Najmanovich, the setbacks ultimately pushed him in a new direction.

View this Issue
Human-Relevant In Vitro Models Enable Predictive Drug Discovery

Advancing Drug Discovery with Complex Human In Vitro Models

Stemcell Technologies
Redefining Immunology Through Advanced Technologies

Redefining Immunology Through Advanced Technologies

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Ensuring Regulatory Compliance in AAV Manufacturing with Analytical Ultracentrifugation

Beckman Coulter Logo
Conceptual multicolored vector image of cancer research, depicting various biomedical approaches to cancer therapy

Maximizing Cancer Research Model Systems

bioxcell

Products

Sino Biological Logo

Sino Biological Pioneers Life Sciences Innovation with High-Quality Bioreagents on Inside Business Today with Bill and Guiliana Rancic

Sino Biological Logo

Sino Biological Expands Research Reagent Portfolio to Support Global Nipah Virus Vaccine and Diagnostic Development

Beckman Coulter

Beckman Coulter Life Sciences Partners with Automata to Accelerate AI-Ready Laboratory Automation

Refeyn logo

Refeyn named in the Sunday Times 100 Tech list of the UK’s fastest-growing technology companies